Barbarino Sheila C, van Loghem Jani A J, Burgess Cheryl M, Corduff Niamh
Dr. Barbarino is with Barbarino Surgical Arts in Austin, Texas.
Dr. Loghem is with the UMA Institute in Amsterdam, the Netherlands.
J Clin Aesthet Dermatol. 2021 Aug;14(8):34-40. Epub 2021 Aug 1.
As aesthetic preferences have evolved and patients wish their muscles to be relaxed, but not frozen, a higher dilution of incobotulinumtoxinA (INCO) has allowed for increased spread using fewer units, yet no studies to date have investigated the efficacy, longevity, and safety of hyperdiluted INCO.
We evaluated the effect of incobotulinumtoxinA (INCO) in glabellar, forehead, and lateral periorbital lines using a high dilution.
Subjects with moderate-to-severe upper facial lines at rest according to the Merz Aesthetics Scales (Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany) received 15U of INCO to the glabellar (n=4 injection sites), 10U to the rest of the forehead (n=10 injection sites), and 5U to the lateral periorbital lines (n=3 injection sites/eye). Primary outcomes were physician- and subject-rated improvement at one month using the Global Aesthetic Improvement Scale (GAIS) and changes in line severity using the Merz Aesthetics Scales.
The study included 15 women aged 35 to 65 years. At one month, physician GAIS scores indicated 91.2% of subjects were very much improved and 8.8% were much improved; 91.5%, 78.0%, and 57.6% of participants remained at least improved at four, five, and six months, respectively. Subject GAIS scores at one month were in agreement with physician scores. At one month, an improvement of at least one point in Merz Aesthetics Scales scores in glabellar, forehead, and lateral periorbital lines was reported in 88.9%, 98.3%, and 94.8% of participants, respectively. Subject satisfaction was high throughout the study. No treatment-related adverse events were observed.
Hyperdilute INCO was effective at improving overall appearance and reducing line severity in individuals with moderate-to-severe upper facial lines. Patient satisfaction was maintained up to six months and treatment was well tolerated.
随着审美偏好的演变，患者希望肌肉放松但不僵硬，更高稀释度的incobotulinumtoxinA（INCO）可使用更少单位实现更大扩散，但迄今为止尚无研究调查超稀释INCO的疗效、持续时间和安全性。
我们评估了高稀释度incobotulinumtoxinA（INCO）用于眉间、额头和眶周外侧纹的效果。
根据默克美学量表（德国美因河畔法兰克福的默克制药有限公司），静息时面部上半部分有中度至重度皱纹的受试者，眉间注射15U的INCO（n = 4个注射部位），额头其他部位注射10U（n = 10个注射部位），眶周外侧纹每只眼睛注射5U（n = 3个注射部位）。主要结局指标为使用全球美学改善量表（GAIS）在1个月时医生和受试者评定的改善情况，以及使用默克美学量表评估的皱纹严重程度变化。
该研究纳入了15名年龄在35至65岁之间的女性。在1个月时，医生的GAIS评分显示91.2%的受试者改善非常明显，8.8%的受试者改善明显；在4、5和6个月时，分别有91.5%、78.0%和57.6%的参与者至少保持改善状态。受试者1个月时的GAIS评分与医生评分一致。在1个月时，分别有88.9%、98.3%和94.8%的参与者报告眉间、额头和眶周外侧纹的默克美学量表评分至少提高了1分。在整个研究过程中，受试者满意度较高。未观察到与治疗相关的不良事件。
超稀释INCO对改善中度至重度面部上半部分皱纹患者的整体外观和减轻皱纹严重程度有效。患者满意度维持长达6个月，且治疗耐受性良好。
